Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Net Income (2019 - 2025)

Historic Net Income for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to -$32.2 million.

  • C4 Therapeutics' Net Income fell 3040.62% to -$32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$119.1 million, marking a year-over-year decrease of 1287.62%. This contributed to the annual value of -$105.3 million for FY2024, which is 2051.2% up from last year.
  • As of Q3 2025, C4 Therapeutics' Net Income stood at -$32.2 million, which was down 3040.62% from -$26.0 million recorded in Q2 2025.
  • C4 Therapeutics' Net Income's 5-year high stood at -$15.7 million during Q4 2021, with a 5-year trough of -$37.2 million in Q4 2022.
  • For the 5-year period, C4 Therapeutics' Net Income averaged around -$28.1 million, with its median value being -$27.0 million (2023).
  • In the last 5 years, C4 Therapeutics' Net Income tumbled by 13748.24% in 2022 and then soared by 5068.2% in 2024.
  • C4 Therapeutics' Net Income (Quarter) stood at -$15.7 million in 2021, then crashed by 137.48% to -$37.2 million in 2022, then rose by 6.54% to -$34.8 million in 2023, then grew by 0.52% to -$34.6 million in 2024, then increased by 6.96% to -$32.2 million in 2025.
  • Its Net Income stands at -$32.2 million for Q3 2025, versus -$26.0 million for Q2 2025 and -$26.3 million for Q1 2025.